Targeting Brain Tumor Stem Cells through Natural Antioxidants
ISEF · 2014 Computational Biology and Bioinformatics Second Award
Overview
Glioblastoma Multiforme is the most frequent and devastating malignant brain tumor among adults with an average life expectancy of one year after diagnosis. This is partly due to its multi-drug resistance and recurrence properties, which have been recently linked to a small sub-population of cancer cells known as brain tumor stem cells (BTSCs). These BTSCs exhibit self-renewal, drug resistance, and tumor initiation capabilities. Current therapies, such as the standard chemotherapy treatment, temozolomide (TMZ), target only cancer cells but not BTSCs. Thus, therapeutic approaches that eradicate the BTSC population must be developed. The objective of this study was to determine the use of natural antioxidants, curcumin, quercetin, and melatonin in targeting BTSCs. Through WST-1 cell proliferation assays it was determined that the addition of curcumin, quercetin, and melatonin resulted in a dose-dependent decrease in proliferation of BTSCs. Interestingly, while treatment with temozolomide induced modest effect, addition of temozolomide in combination with these antioxidants further attenuated BTSC proliferation. Similarly, flow cytometry analyses showed that while treatment with TMZ induced minimal apoptosis and necrosis of BTSCs in culture, treatment with TMZ in combination with these antioxidants further increased apoptotic and necrotic deaths. Further analyses using quantitative real time PCR showed that curcumin, quercetin, and melatonin alone or in combination with TMZ decreased the expression of stemness gene Nanog in BTSCs. These findings demonstrate that these natural antioxidants attenuate growth, survival, and self-renewal of BTSCs, and suggest their use in the treatment of Glioblastoma Multiforme.
Awards (1)
- Second Award of $2,000 $2,000
Competition history
- ISEF 2014
Resources
Related projects
ISEF · 2018
Dihydrotanshinone: A Pan-Therapeutic Treatment for Chemoresistance in Cancer
ISEF · 2014
Treating GBM BTSCs through Growth Factor Stimulation and Drug-Polymer Conjugate Therapy
ISEF · 2023
Sulforaphane and Panobinostat: A Novel Therapy for Glioblastoma Multiforme
ISEF · 2019
TMZ+X: siRNA-based Synthetic Lethal Screening and Synergism with TMZ as a Novel Approach to Inhibition of Proliferation in GBM
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair